Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce the acceptance of a new abstract to be presented at the 2022 AACR Annual Meeting.
Rakovina Therapeutics’ abstract entitled Evaluation of a Novel Class of Bifunctional DNA Alkylating Agent and PARP Inhibitor will be presented at the in-person meeting, which is scheduled to be held April 8th-13th, 2022 in New Orleans, Louisiana.
The AACR Annual meeting aims to connect scientists, clinicians, other health care professionals, cancer survivors and patient advocates from the international cancer research community and facilitate meaningful conversations regarding the full spectrum of cancer science and medicine.
Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series. The company is developing three novel series of DNA-damage response (DDR) inhibitors as potential bio-marker driven treatments across multiple tumor types.
Further information regarding the AARC General Meeting 2022 can be found at: https://www.aacr.org/meeting/aacr-annual-meeting-2022
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response (DDR) technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com.
Rakovina Therapeutics Inc. David Hyman Chief Financial Officer Email: email@example.com Investor Relations Contact IR@rakovinatherapeutics.com Media Contact MEDIA@rakovinatherapeutics.com
#biotech #medicalscience #biotechnews #preclinical #cancerresearch #cancertherapeutics #DNAdamage #DDR #AACR #biotechstocks #preclinical #stockstowatch #pennystocks #FrontierMCG